BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14751145)

  • 1. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma.
    Sebastiani V; Visca P; Botti C; Santeusanio G; Galati GM; Piccini V; Capezzone de Joannon B; Di Tondo U; Alo PL
    Gynecol Oncol; 2004 Jan; 92(1):101-5. PubMed ID: 14751145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma.
    Visca P; Sebastiani V; Pizer ES; Botti C; De Carli P; Filippi S; Monaco S; Alo PL
    Anticancer Res; 2003; 23(1A):335-9. PubMed ID: 12680233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma.
    Visca P; Sebastiani V; Botti C; Diodoro MG; Lasagni RP; Romagnoli F; Brenna A; De Joannon BC; Donnorso RP; Lombardi G; Alo PL
    Anticancer Res; 2004; 24(6):4169-73. PubMed ID: 15736468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue.
    Alò PL; Visca P; Botti C; Galati GM; Sebastiani V; Andreano T; Di Tondo U; Pizer ES
    Am J Clin Pathol; 2001 Jul; 116(1):129-34. PubMed ID: 11447743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid synthase expression in melanoma.
    Innocenzi D; Alò PL; Balzani A; Sebastiani V; Silipo V; La Torre G; Ricciardi G; Bosman C; Calvieri S
    J Cutan Pathol; 2003 Jan; 30(1):23-8. PubMed ID: 12534800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma.
    Khabaz MN; Qureshi IA; Al-Maghrabi JA
    Ginekol Pol; 2019; 90(10):582-588. PubMed ID: 31686415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid synthase expression and clinicopathological findings in endometrial cancer.
    Tsuji T; Yoshinaga M; Togami S; Douchi T; Nagata Y
    Acta Obstet Gynecol Scand; 2004 Jun; 83(6):586-90. PubMed ID: 15144342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia.
    Wang BY; Kalir T; Sabo E; Sherman DE; Cohen C; Burstein DE
    Cancer; 2000 Jun; 88(12):2774-81. PubMed ID: 10870060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of glucose transporter-1 in endometrial hyperplasia and well-differentiated endometrioid adenocarcinoma].
    Liu AJ; Hou N; Chen LZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):398-400. PubMed ID: 12940086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
    Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
    Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival.
    Kawamura T; Kusakabe T; Sugino T; Watanabe K; Fukuda T; Nashimoto A; Honma K; Suzuki T
    Cancer; 2001 Aug; 92(3):634-41. PubMed ID: 11505409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas.
    Al-Maghrabi J; Abdelrahman AS; Ghabrah T; Butt NS; Al-Maghrabi B; Khabaz MN
    Pathol Res Pract; 2017 Apr; 213(4):348-352. PubMed ID: 28215640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic localization of endothelial constitutive nitric oxide synthase in endometrial carcinomas.
    Bentz BG; Barnes MN; Haines GK; Lurain JR; Hanson DG; Radosevich JA
    Tumour Biol; 1997; 18(5):290-300. PubMed ID: 9276029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
    Rossi ED; Bizzarro T; Monterossi G; Inzani F; Fanfani F; Scambia G; Zannoni GF
    Hum Pathol; 2017 Apr; 62():99-107. PubMed ID: 28041971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.